SC
AYTU icon

Searle & Co’s AYTU BioPharma AYTU Stock Holding History

Searle & Co’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-700
Closed -$84K – 142
2020
Q4 		$84K Buy
700
+325
+87% +$59.2K 0.04% 136
2020
Q3 		$89K Buy
375
+250
+200% +$64.3K 0.05% 132
2020
Q2 		$36K Sell
125
-656
-84% -$199K 0.02% 136
2020
Q1 		$234K Sell
781
-581
-43% -$112K 0.17% 104
2019
Q4 		$265K Buy
1,362
+113
+9% +$21.7K 0.15% 116
2019
Q3 		$302K Buy
1,249
+243
+24% +$73.2K 0.18% 103
2019
Q2 		$380K Buy
1,006
+931
+1,241% +$355K 0.23% 95
2019
Q1 		$25K Buy
+75
New +$18.7K 0.02% 127

Other funds holding AYTU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Searle & Co's AYTU Position: Q1 2021 in Review

Searle & Co sold out of AYTU BioPharma (AYTU) in Q1 2021, closing a stake of 700 shares — an estimated $84K sold.

Searle & Co first reported a position in AYTU in Q1 2019 and held it in 8 quarters. The position peaked at $380K in Q2 2019. 64 funds tracked by Wall St. Rank hold AYTU as of Q1 2021.

  • Searle & Co reported no remaining AYTU BioPharma position as of Q1 2021 after selling out during the quarter.
  • Searle & Co sold 700 AYTU BioPharma shares in Q1 2021, an estimated $84K.
  • Searle & Co first reported a position in AYTU BioPharma in Q1 2019 and held it in 8 quarters.
  • Searle & Co's AYTU BioPharma position peaked at $380K in Q2 2019.
  • 64 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2021.

Based on Searle & Co's 13F filing for Q1 2021, filed 12 May 2021.